Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell th...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCI Insight
Auteurs principaux: Walti, Carla S., Krantz, Elizabeth M., Maalouf, Joyce, Boonyaratanakornkit, Jim, Keane-Candib, Jacob, Joncas-Schronce, Laurel, Stevens-Ayers, Terry, Dasgupta, Sayan, Taylor, Justin J., Hirayama, Alexandre V., Bar, Merav, Gardner, Rebecca A., Cowan, Andrew J., Green, Damian J., Boeckh, Michael J., Maloney, David G., Turtle, Cameron J., Hill, Joshua A.
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2021
Sujets:
Clinical Medicine
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262349/
https://ncbi.nlm.nih.gov/pubmed/33914708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.146743
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires